CommercialAdministrativeMedium impact
[Ohio] Lenalidomide is now available with end‑to‑end REMS support
Anthem BCBS·OH · Oncology, Hematology·Provider Bulletin
Effective date
May 1, 2026
We identified it
May 3, 2026
Summary
Lenalidomide is now available through BioPlus Specialty Pharmacy with end-to-end REMS (Risk Evaluation and Mitigation Strategies) management for Ohio commercial plans. BioPlus handles the complete REMS process, reducing administrative burden on providers and accelerating patient access to therapy, including transitions from branded to generic lenalidomide.
Action Required
By May 1, 2026: Providers and billing staff should familiarize themselves with BioPlus Specialty Pharmacy as the designated lenalidomide distributor for this plan. Update internal referral processes and communication templates to direct lenalidomide prescriptions to BioPlus (NCPDP 1078535, Fax: 800-269-5493, bioplusrx.com). Inform prescribing providers that BioPlus manages all REMS requirements end-to-end, reducing the need for provider intervention. Ensure front-desk and billing staff are aware that lenalidomide patients should be routed through BioPlus for both branded and generic formulations. Update provider contact lists with BioPlus information and Availity Chat support availability during business hours for eligibility and authorization questions. No changes to billing codes or claims submission are required, but workflow should reflect this specialty pharmacy designation.